Abstract: 4-(Azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: Also described, are compositions including the same, processes for preparation thereof and uses thereof in pharmaceutical or cosmetic compositions to treat pigmentary disorders.
Abstract: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.
Type:
Grant
Filed:
July 6, 2012
Date of Patent:
March 17, 2015
Assignee:
Galderma Research & Development
Inventors:
Sandrine Rethore, Carine Rosignoli, André Jomard, Johannes Voegel
Abstract: Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions.
Abstract: Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. Melanocortin receptor antagonist compounds corresponding to the general formula (I): compositions containing them, and processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.
Abstract: The invention relates to a composition in the form of a cream gel comprising, in a physiologically acceptable medium, at least one dispersed retinoid and dispersed benzoyl peroxide, to its process of preparation and to its use in cosmetics and in dermatology.
Type:
Grant
Filed:
June 22, 2009
Date of Patent:
February 17, 2015
Assignee:
Galderma Research & Development
Inventors:
Claire Mallard, Fabienne Louis, Emmanuelle At
Abstract: Stable pharmaceutical/cosmetic compositions for topical application, notably for the treatment of acne vulgaris include, formulated into a physiologically acceptable medium, at least one naphthoic acid compound, benzoyl peroxide and at least one film-forming agent, the at least one naphthoic acid compound and the benzoyl peroxide advantageously being in a dispersed form therein.
Abstract: Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound essentially uniformly distributed therethrough and an amount of at least one hydrophilic film-forming agent, formulated into a topically applicable, physiologically acceptable medium.
Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.
Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Abstract: Improved methods and compositions for safe and effective treatment of telangiectasia or a symptom associated with telangiectasia in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
March 25, 2011
Date of Patent:
December 23, 2014
Assignee:
Galderma Research & Development SNC
Inventors:
Michael Graeber, Christian Loesche, Philip Freidenreich, Yin Liu, Matthew James Leoni
Abstract: A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®.
Abstract: Methods, compositions and products for preventing skin tumor formation or inhibiting development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an ?2 adrenergic receptor agonist, such brimonidine.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
December 16, 2014
Assignee:
Galderma Research & Development
Inventors:
Guy Bouvier, Matthew James Leoni, Michael Graeber
Abstract: The use of compounds in the treatment of skin disorders is described. In particular, compounds having the general formula (I): are described. A process for preparing such compounds and their cosmetic or dermatological use are also described. The described compounds can act as bactericides. As a result, they can be useful in the treatment of conditions associated with the presence of bacteria, more specifically of P. acnes.
Type:
Grant
Filed:
December 22, 2010
Date of Patent:
December 2, 2014
Assignee:
Galderma Research & Development
Inventors:
Nicolas Rodeville, Jean-Claude Pascal, Claire Bouix-Peter
Abstract: Melanocortin receptor modulators, processes for preparing them and use thereof in human medicine and cosmetics are described. Melanocortin receptor modulators corresponding to formula (I): compositions containing them, processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.
Abstract: Compounds derived from oxoazetidine corresponding to general formula (I) compositions containing same, processes for their preparation and their use in pharmaceutical or cosmetic compositions are described.
Abstract: A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy.
Abstract: The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): or one of its pharmaceutically acceptable salts, solvates or hydrates in the preparation of a medicament to treat skin pathologies is described.
Abstract: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.
Abstract: A method is described that uses ROR gamma t, or ROR alpha to diagnose rosacea and/or to screen inhibitors of Th17 differentiation, notably in inhibiting ROR gamma t or ROR alpha. Also described is a method of using these screened inhibitors in rosacea treatment.